Home/Pipeline/MN-221

MN-221

Acute Exacerbations of Asthma

Phase 3Active (Strategic Focus)

Key Facts

Indication
Acute Exacerbations of Asthma
Phase
Phase 3
Status
Active (Strategic Focus)
Company

About MediciNova

MediciNova is a clinical-stage biopharma headquartered in La Jolla, California, with a strategy centered on developing and commercializing novel therapeutics in the U.S. market. The company leverages strategic alliances, primarily with Japanese pharmaceutical partners, to build a diversified portfolio of clinical and preclinical candidates. Its current focus is on advancing its lead programs in neurological disorders, acute respiratory conditions, and fibrotic liver disease, while seeking to monetize other assets at key value inflection points.

View full company profile

About MediciNova

MediciNova is a clinical-stage biopharma headquartered in La Jolla, California, with a strategy centered on developing and commercializing novel therapeutics in the U.S. market. The company leverages strategic alliances, primarily with Japanese pharmaceutical partners, to build a diversified portfolio of clinical and preclinical candidates. Its current focus is on advancing its lead programs in neurological disorders, acute respiratory conditions, and fibrotic liver disease, while seeking to monetize other assets at key value inflection points.

View full company profile